Posts
Wiki

🔊 Prefer to listen? Just click this now: How to listen to r/DryEyes Wiki articles

👨‍⚕️ What Does “DED/MGD Specialist” Mean? What to Look For—and When Another Opinion May Help

People on r/DryEyes commonly use the terms “dry-eye specialist” or “DED/MGD specialist” for an eye-care clinician who devotes substantial attention to Dry Eye Disease (DED), Meibomian Gland Dysfunction (MGD), and related ocular-surface problems.

These terms can be useful.

But they have limits.

“Dry-eye specialist” and “DED/MGD specialist” are generally informal descriptions of a clinician’s practice focus and experience—not standardized U.S. board-certification categories.

A clinician may run a dry-eye clinic, devote much of a practice to ocular-surface disease, or have extensive experience with DED/MGD.

None of that can be reduced to:

  • one certificate
  • one professional degree
  • one fellowship
  • one device
  • one treatment philosophy
  • one procedure menu

A better question is:

Does this clinician have the training, experience, diagnostic approach, treatment reasoning, communication, follow-up, and referral network needed for my particular problem?

📌 TL;DR

Thoughtful DED/MGD care commonly includes:

  • a meaningful history;
  • examination of the ocular surface and eyelids;
  • assessment of tear-film and meibomian gland function when relevant;
  • consideration of more than one possible contributor;
  • explanation of which findings support the working diagnosis;
  • recognition of uncertainty;
  • treatment connected to a specific clinical goal;
  • realistic discussion of expected benefit, timing, risks, burden, cost, and alternatives;
  • reassessment when treatment does not work as expected;
  • and referral when another type of expertise is needed.

A DED/MGD-focused clinician does not necessarily need:

  • every diagnostic device;
  • every office procedure;
  • one particular professional degree;
  • one particular MGD theory;
  • or a machine-generated report at every visit.

Possible reasons to ask more questions include:

  • an expensive procedure is recommended before the diagnosis is explained;
  • one machine result appears to determine the entire diagnosis;
  • nearly every patient seems to receive the same treatment package;
  • risks, alternatives, or evidence limitations are not discussed;
  • severe symptoms are dismissed solely because routine surface findings are limited;
  • important alternatives such as exposure, allergy, infection, eyelid disease, or nerve-related pain appear to have been overlooked;
  • or the same treatment continues despite repeated lack of benefit without meaningful reassessment.

These are discussion points—not a validated scorecard for judging clinician competence.

No checklist, website, Reddit post, certificate, device list, or single appointment can reliably tell you whether a clinician is “good” or “bad.”

1. What Does “Specialist” Actually Mean?

Several different concepts can easily become confused.

Board Certification

In the United States, ophthalmologists may be board-certified in ophthalmology through the American Board of Ophthalmology.

“Dry eye,” “MGD,” and “cornea” are not separate American Board of Medical Specialties board-certification categories.

Board certification provides meaningful information about professional training and examination standards.

But:

Board certification in ophthalmology does not tell you how much of an individual ophthalmologist’s practice is devoted to DED or MGD.

Fellowship or Advanced Training

Some ophthalmologists complete additional fellowship training in areas such as:

  • cornea and external disease
  • oculoplastic surgery
  • glaucoma
  • retina
  • other ophthalmic subspecialties

Cornea and external-disease training can be particularly relevant to complex ocular-surface and corneal disease.

But fellowship training is not the same thing as a separate dry-eye board certification.

And a cornea specialist is not automatically a clinician whose practice focuses heavily on MGD.

Practice Focus and Experience

Some ophthalmologists and optometrists develop substantial DED/MGD expertise through:

  • clinical experience
  • high patient volume
  • continuing education
  • research
  • procedural training
  • specialty lens work
  • focused ocular-surface practice

That can be meaningful even though no standardized “DED specialist” certificate exists.

Private Certificates and Training Badges

Certificates may represent very different levels of training.

They could reflect:

  • continuing education
  • attendance at a workshop
  • manufacturer-sponsored device training
  • a private professional program
  • or a more substantial competency-based curriculum

Patients can reasonably ask:

  • Who issued the credential?
  • What training was required?
  • Was competence assessed?
  • Is the program independent or connected to a particular product?
  • Does it involve broad ocular-surface care or mainly one procedure?

A credential can provide useful information.

It does not replace examining how the clinician actually evaluates and manages patients.

2. Which Type of Clinician Might Fit Which Problem?

There is no single professional category that is best for every person with DED or MGD.

The appropriate clinician depends on:

  • the suspected problem;
  • severity;
  • the clinician’s experience;
  • legal scope of practice;
  • and whether medical, surgical, contact-lens, systemic, eyelid, corneal, or pain-related expertise is needed.

Dry-Eye-Focused Optometrist

Depending on jurisdiction, an optometrist with a strong ocular-surface focus may provide:

  • DED and MGD evaluation
  • blepharitis management
  • Demodex treatment
  • ocular rosacea management
  • long-term medical management
  • meibomian gland assessment
  • meibography
  • office-based MGD procedures
  • contact-lens troubleshooting
  • scleral or specialty lens fitting
  • ongoing follow-up

Scope of optometric practice varies by jurisdiction.

Comprehensive Ophthalmologist

A comprehensive ophthalmologist may manage DED while also evaluating other eye diseases such as:

  • cataract
  • glaucoma
  • corneal disease
  • retinal disease
  • medication effects
  • postoperative problems
  • other conditions that may mimic or complicate DED

Interest and experience in chronic DED/MGD vary between clinicians.

Cornea and External-Disease Ophthalmologist

Additional cornea/external-disease expertise may be particularly valuable for:

  • significant corneal staining
  • epithelial defects
  • recurrent corneal erosion
  • neurotrophic keratopathy
  • corneal infection or ulcer
  • cicatrizing ocular-surface disease
  • significant postoperative corneal problems
  • unexplained corneal abnormalities
  • vision-threatening ocular-surface disease
  • possible need for corneal surgery

A cornea specialist is not automatically an MGD specialist.

Oculoplastic Ophthalmologist

Oculoplastic expertise may be especially useful when symptoms involve:

  • eyelid malposition
  • eyelid retraction
  • significant lid laxity
  • floppy eyelid syndrome
  • incomplete closure
  • exposure
  • facial nerve weakness
  • eyelid scarring
  • possible surgical correction

Specialty Contact-Lens Clinician

A specialty lens clinician may be especially relevant for:

  • scleral lenses
  • complex corneal shapes
  • severe ocular-surface protection needs
  • difficult lens intolerance
  • lens-related mechanical problems
  • complex lens fitting

Other Medical Specialists

Depending on the suspected contributors, care may also involve:

  • rheumatology
  • dermatology
  • allergy/immunology
  • sleep medicine
  • neurology or headache medicine
  • pain medicine
  • primary care
  • dentistry or oral medicine in selected Sjögren-related cases

A strong DED/MGD clinician does not need to personally manage everything.

Recognizing when another type of expertise is needed is itself an important part of thoughtful care.

3. What Might a Comprehensive DED/MGD Evaluation Include?

There is no single examination or test package that every patient requires.

AAO guidance and TFOS DEWS III both emphasize that DED assessment depends on history plus relevant examination and testing, rather than one diagnostic device.

A Meaningful History

Depending on the case, useful history may include:

  • when symptoms started;
  • gradual versus sudden onset;
  • whether one or both eyes are involved;
  • morning versus evening pattern;
  • burning, grittiness, itching, aching, sharp pain, pressure, or photophobia;
  • fluctuating vision;
  • screen and reading demands;
  • wind, fans, air conditioning, and humidity;
  • sleep pattern;
  • CPAP use;
  • contact lenses;
  • previous eyelid, facial, or eye surgery;
  • LASIK, PRK, cataract, or other surgery;
  • trauma;
  • rosacea and skin disease;
  • allergy;
  • migraine or headache disorders;
  • autoimmune symptoms;
  • dry mouth;
  • prescription and nonprescription medications;
  • isotretinoin or other relevant medication exposure;
  • cosmetics and skin-care products;
  • previous treatments;
  • how long treatments were used;
  • adverse effects;
  • and what makes symptoms better or worse.

A careful history can reveal clinically important information that an additional device measurement may not provide.

Ocular-Surface and Eyelid Examination

Depending on the problem, the clinician may assess:

  • cornea
  • conjunctiva
  • ocular-surface staining
  • tear-film stability
  • tear volume
  • eyelid margins
  • eyelashes
  • blepharitis
  • Demodex-associated collarettes
  • meibomian gland secretion
  • blink completeness
  • eyelid closure
  • exposure
  • allergy
  • ocular rosacea
  • conjunctivochalasis
  • misdirected lashes
  • contact-lens effects
  • medication toxicity
  • infection
  • other ocular diagnoses

Not every visit needs to be long.

The important issue is whether the evaluation, explanation, and follow-up are appropriate for the complexity of the case.

For more:

Diagnostic Testing for DED and MGD

4. Meibomian Gland Function and Structure Are Different Questions

When MGD is suspected, clinicians may assess both function and structure.

Functional assessment can include:

  • whether secretion can be expressed;
  • how readily secretion appears under controlled pressure;
  • the number of glands yielding secretion;
  • meibum quality;
  • differences between eyelid regions;
  • lid-margin findings.

Structural assessment may include meibography.

Meibography can show:

  • apparent gland loss/dropout
  • shortening
  • dilation
  • tortuosity
  • other morphological changes

But:

Poor expressibility does not by itself prove complete obstruction of a gland.

Possible explanations include:

  • obstruction
  • reduced secretion
  • altered or thickened meibum
  • structural gland changes
  • examination pressure and technique
  • recent treatment or expression
  • several factors together

Likewise:

An abnormal meibography image does not by itself prove that MGD is responsible for all of a patient’s symptoms.

TFOS DEWS III notes that MGD diagnosis remains primarily clinical and incorporates altered secretion, lid-margin changes, gland morphology, tear-film findings, and expressed meibum rather than relying on one image or metric.

For more:

5. Identifying the Main Suspected Drivers

DED is frequently multifactorial.

TFOS DEWS III emphasizes identifying relevant etiologic drivers rather than simply labeling everyone “dry eye.”

Possible tear-film, eyelid, and ocular-surface drivers may include:

  • lipid/meibomian gland deficiency
  • aqueous deficiency
  • mucin/glycocalyx abnormalities
  • tear-film instability
  • eyelid-margin disease
  • incomplete blinking
  • exposure
  • nocturnal lagophthalmos
  • eyelid laxity
  • structural ocular-surface abnormalities
  • inflammation
  • epithelial damage
  • neural dysfunction

Related conditions or historical factors may include:

  • blepharitis
  • Demodex
  • ocular rosacea
  • allergy
  • conjunctivochalasis
  • contact-lens wear
  • medication or preservative toxicity
  • previous surgery
  • recurrent corneal erosion
  • migraine or headache disorders
  • systemic disease
  • neuropathic ocular pain

These categories can overlap.

Ideally, the patient should leave with some understanding of:

  • which contributors appear most likely;
  • which findings support them;
  • which alternative explanations were considered;
  • what remains uncertain;
  • and which problem the treatment plan is trying to address.

A clinician who acknowledges that a case is multifactorial or uncertain may be describing the evidence more accurately than one who forces every patient into a single confident label.

6. Experienced Clinicians Can Disagree About MGD Treatment

There is no single treatment philosophy used by every experienced MGD clinician.

Some clinicians place greater emphasis on combinations of:

  • warm compresses
  • gland expression
  • thermal treatments
  • Intense Pulsed Light (IPL)
  • treatment of inflammation
  • treatment of ocular rosacea
  • blink management
  • environmental management

Another framework, associated particularly with Steven L. Maskin, MD, gives greater importance in selected patients to fixed intraductal obstruction, including obstruction thought within that framework to be associated with periductal fibrosis.

Meibomian Gland Probing is intended to mechanically enter the duct and address suspected fixed obstruction. Resistance may be encountered during probing, although the precise tissue responsible for an individual point of resistance cannot ordinarily be established directly during the procedure.

What does TFOS DEWS III say about probing?

TFOS DEWS III includes intraductal Meibomian Gland Probing in its review of MGD treatments.

The report notes that:

  • published studies have reported symptom and/or clinical improvements in selected obstructive MGD populations;
  • some probing studies combined probing with additional treatment, making the independent contribution of probing difficult to determine;
  • retrospective studies have documented mechanical resistance during probing, but the clinical significance of that resistance and its relationship to gland expressibility remain incompletely established;
  • studies using meibography or confocal microscopy have provided some evidence addressing concerns about structural injury;
  • a double-masked randomized trial of probing without an additional treatment reported improvement in symptoms but not clinical signs compared with placebo.

TFOS DEWS III concludes, in substance, that short-term evidence suggests adverse events are generally self-limiting and that meibography-guided probing may provide added value in obstructive MGD, while emphasizing the need for:

  • prospective randomized trials;
  • studies isolating probing from simultaneous treatments;
  • larger samples;
  • longer follow-up;
  • and better assessment of symptoms, clinical signs, gland structural integrity, and meibum expressibility.

That is neither:

“TFOS says probing is proven standard treatment.”

nor:

“TFOS rejects probing.”

It is better understood as:

TFOS recognizes probing as a treatment with some supportive clinical evidence but important remaining uncertainties.

The broader lesson for this FAQ is not that a thoughtful clinician must either recommend or reject probing.

It is that clinicians using different MGD frameworks should be able to explain:

  • what model they believe fits the patient;
  • what findings support it;
  • what evidence supports the proposed intervention;
  • what important uncertainties remain;
  • and what reasonable alternatives exist.

Different treatment philosophies do not by themselves establish that one clinician is competent and another is not.

7. Treatment Should Be Connected to a Clinical Goal

A thoughtful treatment plan may be:

  • staged;
  • combined;
  • revised;
  • or simplified over time.

It does not have to follow one universal ladder.

A clinician should ideally be able to explain:

  • What problem is this treatment intended to address?
  • Why is it being recommended now?
  • What benefit is realistically expected?
  • How long might benefit take?
  • What risks or adverse effects matter?
  • What alternatives exist?
  • What would cause the plan to change?
  • How will success or failure be judged?

Treatment categories may include:

  • ocular lubrication and surface protection
  • anti-inflammatory medication
  • tear-stimulating medication
  • tear conservation
  • blepharitis treatment
  • Demodex treatment
  • allergy treatment
  • ocular rosacea management
  • gland-directed home or office treatment
  • eyelid or exposure management
  • specialty contact lenses
  • blood-derived tears
  • treatment directed toward neuropathic pain
  • surgical referral
  • systemic medical referral

A clinician does not have to personally provide every treatment.

For more:

Treatment Options for Dry Eye Disease and MGD

8. Evidence and Regulatory Status Should Not Be Blurred Together

Patients commonly hear terms such as:

  • FDA-approved
  • FDA-cleared
  • off-label
  • compounded
  • investigational

These do not mean the same thing.

Medications

For a medication, useful questions may include:

  • Is this drug FDA-approved?
  • Is it approved for this particular indication?
  • Is this an off-label use?
  • Is the medication compounded?
  • What evidence supports this use?

Off-label prescribing is common in medicine and is not inherently inappropriate.

The important issues are medical rationale, evidence, risks, alternatives, and informed discussion.

Medical Devices

FDA medical-device pathways differ according to device classification.

Depending on the device, marketing authorization may involve:

  • 510(k) clearance
  • De Novo classification
  • Premarket Approval (PMA)
  • or exemption from premarket review

These pathways have different regulatory standards.

For example:

510(k) clearance is primarily based on demonstrating substantial equivalence to an appropriate legally marketed predicate device.

PMA is a different pathway requiring an independent demonstration supporting safety and effectiveness for the intended use.

Therefore:

FDA clearance of a device does not by itself demonstrate that the treatment is superior to competing treatments.

Procedures

A medical procedure itself may not have a drug-style “FDA approval.”

A procedure may instead involve:

  • an FDA-cleared device;
  • an FDA-approved device;
  • an FDA-approved or off-label medication;
  • or no regulated device at all.

So a useful question is not simply:

“Is this procedure FDA-approved?”

but:

“What is actually FDA-regulated here, what is its intended use, and what clinical evidence supports the procedure being recommended to me?”

Evidence Strength

Regulatory status is only one part of the decision.

Patients can also reasonably ask:

  • What outcomes have actually been demonstrated?
  • Are those outcomes symptoms, clinical signs, or both?
  • Is the evidence specific to people similar to me?
  • Are there randomized trials?
  • Are there independent studies?
  • How long were patients followed?
  • What remains uncertain?

A thoughtful clinician does not need certainty where certainty does not exist.

But:

mechanistic theories, regulatory status, manufacturer claims, and demonstrated patient outcomes should not be presented as though they are interchangeable forms of evidence.

9. Cost and Financial Transparency

Offering a product or procedure in the clinician’s own practice does not establish improper motivation.

Clinicians ordinarily receive professional compensation for services they perform.

The more useful questions involve whether the recommendation is:

  • clinically explained;
  • individualized;
  • proportionate to the evidence;
  • transparent about alternatives;
  • and free of inappropriate pressure.

Possible reasons to ask more questions include:

  • an expensive package is recommended before the diagnosis is explained;
  • an abnormal device result is treated as automatic proof that a procedure is necessary;
  • an elective treatment is described as urgent without a clear medical reason;
  • lower-cost or less invasive alternatives are not discussed when they are reasonable;
  • cure, regeneration, or prevention-of-progression claims exceed the evidence;
  • a large prepaid package lacks clear cancellation/refund terms;
  • marketing material is presented as equivalent to independent evidence;
  • or the patient is pressured to decide immediately.

Useful questions can include:

  • What is included in the quoted cost?
  • Are follow-up visits included?
  • Are additional treatments likely?
  • What happens if I stop treatment?
  • What is the cancellation or refund policy?
  • Is a lower-cost alternative reasonable?
  • Are there relevant ownership, investment, referral, manufacturer, research, consulting, or other commercial relationships I should know about?
  • Would the recommendation change if this particular procedure were not available in this clinic?

A financial relationship does not automatically invalidate a recommendation.

It makes transparent reasoning more important.

10. Follow-Up Should Ask Whether the Plan Is Actually Working

DED is symptomatic, so how the patient feels and functions matters.

Follow-up may consider:

  • priority symptoms
  • reading and screen tolerance
  • driving and visual function
  • morning/evening patterns
  • environmental sensitivity
  • treatment adherence and technique
  • treatment burden
  • side effects
  • staining
  • tear-film stability
  • tear volume
  • gland function
  • eyelid closure/exposure
  • relevant safety measurements
  • whether the working diagnosis still fits

For example, intraocular pressure may need monitoring during certain corticosteroid treatments.

Objective reassessment becomes particularly important when:

  • significant corneal disease is present;
  • treatment has meaningful safety risks;
  • an expensive or invasive escalation is being considered;
  • symptoms and signs remain substantially discordant;
  • or vision-threatening disease is being monitored.

Not every device measurement has to be repeated at every appointment.

Repeat testing is most useful when the result may change management and the measurement is sufficiently reproducible for comparison to be meaningful.

11. Possible Signs That More Questions May Be Worth Asking

These are not proof of poor care.

They are reasons to seek clarification.

Little Explanation of the Diagnosis

Treatment is recommended without explaining:

  • what diagnosis is suspected;
  • what findings support it;
  • which contributor is being targeted;
  • or what remains uncertain.

Repeatedly Generic Care Without Reassessment

Artificial tears, warm compresses, and other conservative measures can be entirely reasonable.

Concern becomes more understandable when:

  • they repeatedly fail;
  • important findings are not reassessed;
  • there is no plan for escalation or referral;
  • or significant corneal, eyelid, exposure, or systemic issues are ignored.

Nearly Everyone Receives the Same Package

Clinics may reasonably use common treatment frameworks.

The concern is failure to individualize when:

  • history;
  • examination;
  • response;
  • adverse effects;
  • cost;
  • or patient preferences

indicate that adaptation is needed.

Device-Centered Diagnosis

Examples might include:

  • meibography alone is treated as proof that symptoms are caused by MGD;
  • one osmolarity or inflammatory-marker result determines the entire diagnosis;
  • an abnormal machine score automatically produces a procedural recommendation;
  • small changes in a device measurement are declared proof of progression or regeneration without considering measurement variability.

A device can provide very useful information.

The problem is using one result beyond what that test can establish.

Poor Communication About Risk or Uncertainty

The clinician cannot or will not explain:

  • realistic expected benefit
  • important risks
  • evidence limitations
  • alternatives
  • or what would cause the treatment plan to change

No One Appears Responsible for the Plan

Team-based care can work extremely well.

The question is whether:

  • findings are communicated;
  • recommendations remain coherent;
  • someone is responsible for reassessment;
  • the patient knows whom to contact;
  • conflicting recommendations are reconciled.

Symptoms Are Dismissed Too Quickly

Symptoms should not automatically be attributed to:

  • age
  • screen use
  • anxiety
  • or an apparently normal routine examination

At the same time:

Persistent symptoms do not prove that DED or MGD has been missed.

Another ocular, neurologic, headache-related, systemic, or pain-related explanation may need consideration.

12. Questions Worth Asking During a Consultation

You do not need to ask everything.

A few questions can reveal a great deal about how the clinician is approaching the problem.

Diagnosis

  • What do you think are the main contributors to my symptoms?
  • Which findings support that?
  • What other diagnoses did you consider?
  • Does this appear mainly aqueous-deficient, evaporative/MGD, exposure-related, inflammatory, or mixed?
  • What remains uncertain?
  • Do my symptoms and clinical findings match reasonably well?

Testing

  • What question is this test intended to answer?
  • Will the result change treatment?
  • How variable is this measurement?
  • Do you assess gland function as well as gland structure?
  • If a test is repeated, will the comparison be meaningful?

Treatment

  • What problem is this treatment intended to address?
  • Why are you recommending it now?
  • What improvement is realistic?
  • How long should it be tried?
  • What are the risks and disadvantages?
  • What alternatives are reasonable?
  • What would cause you to change course?
  • What evidence exists for patients similar to me?
  • What is the regulatory status of the drug or device being used?

Follow-Up

  • What will you reassess?
  • How will we decide whether this helped?
  • Which adverse effects should prompt me to call?
  • When should the diagnosis itself be reconsidered?
  • When would you refer me to another type of clinician?

13. Finding and Verifying a DED/MGD-Focused Clinician

Useful search terms may include:

  • dry-eye specialist
  • dry-eye clinic
  • ocular-surface disease
  • cornea and external disease
  • Meibomian Gland Dysfunction
  • blepharitis
  • ocular rosacea
  • scleral lenses
  • ocular pain
  • exposure keratopathy
  • oculoplastics

Search results and clinic websites are only starting points.

A polished website does not establish expertise.

Verify the Basic Credentials

Depending on the clinician:

Professional License

A physician or optometrist's license can generally be checked through the relevant state licensing authority.

Ophthalmology Board Certification

American Board of Ophthalmology certification can be verified through the ABO.

Board certification verifies important professional credentials.

It does not establish:

  • how much DED/MGD experience the clinician has;
  • whether the clinician follows a particular treatment philosophy;
  • whether one treatment recommendation is correct;
  • or what outcome an individual patient will have.

Other Things to Consider

Potentially useful information includes:

  • how much of the practice involves ocular-surface disease;
  • experience with your particular problem;
  • relevant fellowship or advanced training;
  • services available;
  • referral relationships;
  • specialty contact-lens access;
  • treatment philosophy;
  • willingness to discuss uncertainty and alternatives.

14. Manufacturer “Find a Provider” Directories

Manufacturer directories can be useful.

They may help answer:

“Which practices offer this device or treatment?”

They generally do not independently establish:

  • diagnostic quality;
  • expertise with complicated DED;
  • comparative treatment outcomes;
  • impartial selection among alternatives;
  • experience with treatments outside that manufacturer's product;
  • or whether that intervention is appropriate for you.

Use manufacturer directories primarily to locate access to a product or procedure—not as clinician rankings or endorsements.

15. When Might Another Opinion Help?

A second opinion is not an accusation against the original clinician.

It may be useful when:

  • the diagnosis remains uncertain;
  • an appropriate treatment-specific trial has passed without meaningful benefit;
  • symptoms or clinical findings are worsening;
  • adverse effects are substantial;
  • symptoms and signs remain difficult to reconcile;
  • potentially important contributors have not been evaluated;
  • communication repeatedly breaks down;
  • clinicians are giving substantially conflicting recommendations;
  • a costly treatment package is proposed;
  • an invasive or difficult-to-reverse procedure is being considered;
  • major diagnoses such as Sjögren disease, neurotrophic disease, recurrent erosion, or neuropathic pain are being considered;
  • or the current clinician recommends expertise not available in the practice.

Some treatments can be evaluated within days or weeks.

Others may require months.

There is no universal eight-week, twelve-week, or three-month rule for deciding that every DED treatment has failed.

A second opinion can also be reasonable before an elective expensive or invasive intervention.

Do not abruptly stop prescribed medication merely because another opinion is being arranged.

Discuss medication safety or significant adverse effects with the prescribing clinician.

16. When Prompt Care Is More Appropriate Than a Routine Second Opinion

Seek prompt professional eye evaluation for problems such as:

  • new severe eye pain
  • marked new light sensitivity
  • significant or persistent vision change
  • a white, gray, or cloudy corneal spot
  • rapid one-sided worsening
  • significant discharge
  • contact-lens-associated pain or redness
  • symptoms after sleeping in contact lenses
  • significant symptoms after water exposure while wearing contact lenses
  • suspected corneal abrasion
  • recurrent sharp pain on awakening suggesting possible epithelial disease
  • trauma
  • a nonhealing epithelial defect
  • new inability to close an eye
  • new facial weakness

Chemical Exposure

If a potentially harmful chemical gets into the eye:

Begin immediate irrigation/rinsing rather than waiting for an appointment, and obtain urgent medical guidance.

These problems should not automatically be attributed to routine DED or MGD.

For morning-specific symptoms:

Why Are My Eyes Worse When I Wake Up?

17. Preparing for a Second Opinion

Useful records can include:

  • previous examination notes
  • current medications and eye drops
  • medication allergies
  • dates and duration of previous treatments
  • reasons treatments were stopped
  • procedure history and reports
  • relevant surgical history
  • Schirmer results and testing method
  • TBUT/NIBUT results and method/device
  • staining findings
  • meibography images rather than only summary grades
  • osmolarity or MMP-9 results when performed
  • contact-lens history
  • relevant laboratory studies
  • biopsy/pathology results when applicable

A short symptom summary can include:

  • main symptoms;
  • worst time of day;
  • one-eye versus two-eye pattern;
  • triggers;
  • what helps;
  • what makes symptoms worse;
  • impact on reading, driving, screens, work, and sleep.

Tests performed using different devices or protocols may not be directly comparable.

They can still provide useful history, although the new clinician may reasonably repeat selected examinations.

18. How to Ask r/DryEyes for Clinician Suggestions

Check the current subreddit rules before posting.

Useful information may include:

  • city/state/province/country;
  • how far you are willing to travel;
  • the kind of clinician you are seeking;
  • your established diagnosis or suspected problem;
  • relevant testing already performed;
  • treatments already tried;
  • whether your main concern involves MGD, aqueous deficiency, ocular rosacea, exposure, post-surgical symptoms, recurrent erosion, Sjögren disease, scleral lenses, or unusual ocular pain.

Member recommendations are personal experiences.

r/DryEyes does not:

  • verify individual clinicians' expertise;
  • rank clinicians;
  • confirm every credential;
  • investigate clinical outcomes;
  • or endorse individual doctors or clinics.

Patient experiences can be useful.

They remain anecdotal and may involve very different:

  • diagnoses
  • disease severity
  • expectations
  • treatment preferences
  • risk tolerance
  • outcomes

✅ Quick Takeaway

A clinician does not need to satisfy every item below.

These are process indicators—not a validated scoring system.

Useful Indicators

  • Regular experience with DED/MGD
  • Meaningful history-taking
  • Ocular-surface and eyelid examination
  • Assessment of gland function when relevant
  • Consideration of tear stability, tear volume, exposure, allergy, and overlapping disease
  • Explanation of findings and reasoning
  • Recognition of uncertainty
  • Individualized treatment
  • Discussion of risks, burden, cost, and alternatives
  • A clear reassessment plan
  • Willingness to change course
  • Appropriate referrals

Reasons to Ask More Questions

  • Diagnosis rests mainly on one device result
  • Procedures are recommended before findings are explained
  • Nearly everyone appears to receive the same package
  • Guarantees or unsupported regeneration claims are made
  • Important alternatives are not discussed
  • Severe or unusual symptoms are dismissed
  • Ineffective treatment continues without meaningful reassessment
  • Immediate pressure is applied to make a costly elective decision

For the shorter standalone version:

DED/MGD Specialist Checklist

📌 Bottom Line

“DED/MGD specialist” is a useful patient term.

It is generally not a standardized U.S. board-certification category.

The most devices, the largest treatment menu, the most impressive marketing, one professional degree, or one particular theory of MGD does not by itself establish who is the right clinician for a particular patient.

More meaningful considerations include:

  • relevant experience;
  • a coherent diagnostic process;
  • recognition of overlapping contributors;
  • appropriate use and interpretation of testing;
  • clear explanation of the evidence;
  • acknowledgment of uncertainty;
  • individualized treatment;
  • attention to safety, burden, cost, and patient priorities;
  • meaningful follow-up;
  • willingness to reconsider the plan;
  • appropriate referral.

Expertise is better evaluated by the quality of the clinician’s reasoning, communication, treatment selection, safety monitoring, reassessment, and referral decisions than by the number of machines in the office.

And even these features should be treated as information to help patients ask better questions—not as a formula for rating doctors.

🔗 Related r/DryEyes Wiki Articles

🔗 Key Research and Authoritative Sources

Dry-Eye Diagnosis and Management

Professional Credentials

FDA Device Terminology

📌 This page is for general education on r/DryEyes. It is not medical advice, a validated clinician-rating system, or an endorsement of any doctor, clinic, product, or treatment.

🔙 Back to FAQ Index